KRAS G12C inhibition produces a driver-limited state revealing collateral dependencies

Lou, Kevin, Steri, Veronica, Ge, Alex Y., Hwang, Y. Christina, Yogodzinski, Christopher H., Shkedi, Arielle R., Choi, Alex L. M., Mitchell, Dominique C. +5 more·2019·Science Signaling
DOI 10.1126/scisignal.aaw9450

Cited by (175)

Items 101–175 of 175

  1. Assessment of KRASG12C inhibitors for colorectal cancer
    Gary Anthony Piazza, Preethi Chandrasekaran, Yulia Y. Maxuitenko, Karim I. Budhwani · 2024 · Frontiers in Oncology
  2. Drugging the Undruggable and beyond: Emerging precision oncology approaches to target acquired resistance to KRAS G12C and KRAS G12D inhibitors
    Ramesh R. Kale, Charudatt Samant, Krishnadas Nandakumar, Karkala Sreedhara Ranganath Pai, Mandar Bhonde · 2025 · Biochemical and Biophysical Research Communications
  3. dCas9 techniques for transcriptional repression in mammalian cells: Progress, applications and challenges
    Yuanyuan Li, Liquan Zhou · 2021 · BioEssays
  4. AzidoTMT Enables Direct Enrichment and Highly Multiplexed Quantitation of Proteome-Wide Functional Residues
    Taylur P. Ma, Anita Izrael-Tomasevic, Rana M Mroue, Hanna G. Budayeva, Sushant Malhotra, Ryan M. Raisner, Marie Evangelista, Christopher M. Rose, Donald S. Kirkpatrick, Kebing Yu · 2023 · Journal of Proteome Research
  5. New insights into RAS in head and neck cancer
    Sankar Jagadeeshan, Ofra Novoplansky, Oded M. Cohen, Ina Kurth, Jochen Heß, Ari Joseph Rosenberg, Jennifer Rubin Grandis, Moshe Elkabets · 2023 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
  6. Identification of Potential Inhibitors Targeting GTPase-Kirsten RAt Sarcoma Virus (K-Ras) Driven Cancers via E-Pharmacophore-Based Virtual Screening and Drug Repurposing Approach
    S. Udhaya Kumar, Rinku Polachirakkal Varghese, V. Anu Preethi, C. George Priya Doss, Hatem Zayed · 2023 · Frontiers in Bioscience-Landmark
  7. Genome-wide CRISPR screens for the identification of therapeutic targets for cancer treatment
    Vivian Weiwen Xue, Sze Chuen Cesar Wong, William Chi Shing Cho · 2020 · Expert Opinion on Therapeutic Targets
  8. Silver Nanoparticles with Dual-Recognition via CRISPR/dCas9 for SERS Identification of Two KRAS Mutations in Nucleic Acid Targets
    Ailing Su, Yuan Liu, Weihan Sun, Chongyang Liang, Weiqing Xu, Alison Rodger, James A. Piper, Yuling Wang, Shuping Xu · 2024 · ACS Applied Nano Materials
  9. Ferredoxin 1: a gatekeeper in halting lung adenocarcinoma progression through activation of the GPRIN2 signaling pathway
    Ming Rong Liu, Shaoxian Wu, Haoyu Wu, You Zhou, Xinyu Zhang, Dawei Zhu, Jingting Jiang · 2024 · Journal of Translational Medicine
  10. Use of Personalized Biomarkers in Metastatic Colorectal Cancer and the Impact of AI
    Simona Ruxandra Volovăț, Iolanda Georgiana Augustin, Daniela Zob, Diana Boboc, Florin Amurariti, Constantin D. Volovat, Cipriana Ştefănescu, Cati Raluca Stolniceanu, Manuela Ciocoiu, Eduard Alexandru Dumitras et al. · 2022 · Cancers
  11. Small Molecule Imaging Agent for Mutant KRAS G12C
    Peter David Koch, Jeremy M. Quintana, Maaz S. Ahmed, Rainer H. Köhler, Ralph Weissleder · 2021 · Advanced Therapeutics
  12. Inhibitors of the GTPase KRASG12Cin cancer: a patent review (2019-2021)
    Qifu Xu, Guozhen Zhang, Qian Liu, Shunda Li, Yingjie Zhang · 2022 · Expert Opinion on Therapeutic Patents
  13. RAS and Other Molecular Targets in Pancreatic Cancer: The Next Wave Is Coming
    Lisa Miller‐Phillips, Eric Andrew Collisson · 2023 · Current Treatment Options in Oncology
  14. PKN2 Is a Dependency of the Mesenchymal-like Cancer Cell State
    Shane T. Killarney, Gabriel Mesa, Rachel Washart, Benjamin Mayro, Kerry A. Dillon, Suzanne E. Wardell, Madeline Newlin, Min Lu, Areej Abu Rmaileh, Nicky Liu et al. · 2024 · Cancer Discovery
  15. KRAS-targeted therapies in cancer: novel approaches and overcoming resistance
    Daolin Tang, Guido Kroemer, Rui Kang · 2025 · BMJ Oncology
  16. The GENEVA platform models tumor mosaicism to reveal variations of responses to KRAS inhibitors and identify improved drug combinations
    Johnny X. Yu, Jung Min Suh, Katerina D. Popova, Kristle Garcia, Tanvi V. Joshi, Bruce Culbertson, Jessica B. Spinelli, Vishvak Subramanyam, Kevin Lou, Trey Charbonneau et al. · 2026 · Nature Cancer
  17. Pancreatic cancer driver mutations are targetable through distant alternative RNA splicing dependencies
    Ryan R. Kawalerski, Steven D. Leach, Luisa F. Escobar‐Hoyos · 2021 · Oncotarget
  18. Discovery of novel coumarin-based KRAS-G12C inhibitors from virtual screening and Rational structural optimization
    Jian-Tao Shi, Su-Juan Hou, Lei Cheng, Haojie Zhang, Hong-Xia Mu, Qingshan Wang, Zhaoyang Wang, Shi‐Wu Chen · 2024 · Bioorganic Chemistry
  19. Posttranslational modifications remodel proteome-wide ligandability
    Weichao Li, Qijia Wei, Manuel A. Llanos, Clara Gathmann, Paolo Governa, Tzu-Yuan Chiu, Jacob M. Wozniak, Appaso M. Jadhav, Matthew Holcomb, Jacob B. Cravatt et al. · 2026 · Nature Chemical Biology
  20. CRISPR knockout screens reveal JUN as the master mediator of resistance to MAPK inhibition in KRAS-mutant pancreatic cancer
    Antonio Mulero‐Sánchez, Astrid R. Bosma, Bonifiya Visuvasam, Niki Pouliopoulou, Marieke van de Ven, Natalie Proost, Manon Boeije, Cor Lieftink, Roderick L. Beijersbergen, René Bernards et al. · 2026 · Journal of Experimental & Clinical Cancer Research
  21. If Virchow and Ehrlich Had Dreamt Together: What the Future Holds for KRAS-Mutant Lung Cancer
    Jens Köhler, Pasi Antero Janne · 2021 · International Journal of Molecular Sciences
  22. The Selective WEE1 Inhibitor Azenosertib Shows Synergistic Antitumor Activity with KRAS G12C Inhibitors in Preclinical Models
    Nathan M. Jameson, Daehwan Kim, Catherine Lee, Blake Skrable, Alexandra Shea, Xiao Guo, Hooman Izadi, Mona Abed, Olivier Harismendy, Jianhui Ma et al. · 2025 · Cancer Research Communications
  23. Cytotoxic activity of KRAS inhibitors in combination with chemotherapeutics
    Gerhard Hamilton, Adelina Plangger · 2021 · Expert Opinion on Drug Metabolism & Toxicology
  24. Enhancing the Therapeutic Efficacy of KRASG12C Inhibitors in Lung Adenocarcinoma Cell Models by Cotargeting the MAPK Pathway or HSP90
    Ying Liu, Lei Wu, Hong Lü, En Wu, Jun Ni, Xiaorong Zhou · 2021 · Journal of Oncology
  25. Aurora kinase blockade drives de novo addiction of cervical squamous cell carcinoma to druggable EGFR signalling
    Masayuki Komatsu, Kanako Nakamura, Takashi Takeda, Fumiko Chiwaki, Kouji Banno, Daisuke Aoki, Fumitaka Takeshita, Hiroki Sasaki · 2022 · Oncogene
  26. Pan‐ERBB Inhibitors Synergize With KRAS Inhibitors in Rectal Cancer
    Jonas Buchloh, Melanie Spitzner, Hauke Zimmermann, Xin Fang, Constanza Tapia Contreras, Carolin Schneider, Tiago de Oliveria, Stefan Küffer, Michael Linnebacher, Felix Rühlmann et al. · 2025 · United European Gastroenterology Journal
  27. Wild-type RAS signaling is an essential therapeutic target in RAS -mutated cancers
    Nancy E. Sealover, Bridget A. Finniff, Jacob M. Hughes, Erin Sheffels, Hyun Lee, Joseph P. LaMorte, Vainavi Gambhir, Zaria Beckley, Amanda J. Linke, Matthew D. Wilkerson et al. · 2025 · Science Signaling
  28. Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation
    Panyu Chen, Benjamin J. Huang, Max Harris, Christopher D. Boone, Weijie Wang, Heidi Carias, Brian Mesiona, Daniela Mavrici, Amanda C. Kohler, Gideon E. Bollag et al. · 2023 · JCI Insight
  29. Combinatorial approaches for mitigating resistance to KRAS-targeted therapies
    Hannah R. Warren, Sarah J. Ross, Paul D. Smith, Judy M. Coulson, Ian A. Prior · 2022 · Biochemical Journal
  30. Understanding and drugging RAS: 40 years to break the tip of the iceberg
    Donita C. Brady, Julija Hmeljak, Arvin C. Dar · 2022 · Disease Models & Mechanisms
  31. mTORC1 activity suppresses ferroptosis through a SCARB1-dependent HDL-tocopherol uptake pathway
    Thomas A. O’Loughlin, John S. Stiles, Pritika Acharya, Abolfazl Arab, Laine Goudy, Raymond Dai, Ashir A. Borah, William A. Weiss, Uche N. Medoh, Luke A. Gilbert · 2026 · Molecular Cell
  32. The Target Therapy Hyperbole: “KRAS (p.G12C)”—The Simplification of a Complex Biological Problem
    Massimiliano Chetta, Anna Basile, Marina Tarsitano, Maria Rivieccio, Maria Oro, Nazzareno Capitanio, Nenad Bukvić, Manuela Priolo, Alessandra Rosati · 2024 · Cancers
  33. Mapping cancer genetics at single-cell resolution
    Luke A. Gilbert · 2020 · Science Translational Medicine
  34. A global cancer data integrator reveals principles of synthetic lethality, sex disparity and immunotherapy
    Christopher Yogodzinski, Abolfazl Arab, Justin R. Pritchard, Hani Goodarzi, Luke A. Gilbert · 2021 · Genome Medicine
  35. Oncogenic KRAS addiction states differentially influence MTH1 expression and 8-oxodGTPase activity in lung adenocarcinoma
    Beatriz Mateo-Victoriano, Govindi J. Samaranayake, Sheela Pangeni Pokharel, Gracy Jenifer Sahayanathan, Christina J. Jayaraj, Clara I. Troccoli, Dionysios Christos Watson, Michael G. Mohsen, Yan Guo, Eric T. Kool et al. · 2025 · Redox Biology
  36. Simultaneous targeting of KRAS and CDK4 synergistically induces durable growth arrest in pancreatic cancer cells
    Maj-Britt Paulsohn, Klara Henrike Frahnert, Denise Schlösser, Joana Oschwald, Waltraut Kopp, Xin Fang, Carolin Schneider, Constanza Tapia Contreras, Adi Danieli‐Mackay, Fabian Ludewig et al. · 2025 · Cell Death and Disease
  37. Isoform-specific single-cell perturb-seq reveals distinct functions of alternative promoters in drug response
    Helen E King, Savannah O’Connell, Daisy Kavanagh, Sofia Mason, Cerys S. McCool, Javier Fernández-Chamorro, Christine Louise Chaffer, Susan J. Clark, Helaine Graziele Santos Vieira, Timothy Sterne-Weiler et al. · 2026 · Nucleic Acids Research
  38. Evolution of computational techniques against various KRAS mutants in search for therapeutic drugs: a review article
    Ayesha Mehmood, Mohammed Ageeli Hakami, Hanan A. Ogaly, Vetriselvan Subramaniyan, Asaad Khalid, Abdul Wadood · 2025 · Cancer Chemotherapy and Pharmacology
  39. Drugging the undruggable: Advances in targeting KRAS signaling in solid tumors
    Prajna Tripathi, Rajni Kumari, Rajiv Pathak · 2024 · International review of cytology
  40. CRISPRing KRAS: A Winding Road with a Bright Future in Basic and Translational Cancer Research
    Xian Gong, Jianting Du, Ren‐Wang Peng, Chun Chen, Yang Zhang · 2024 · Cancers
  41. Harnessing CRISPR/Cas9 to overcome targeted therapy resistance in non‑small cell lung cancer: Advances and challenges (Review)
    Jianting Du, Xian Gong, Renjie Huang, Bin Zheng, Chun Chen, Yang Zhang · 2025 · Oncology Reports
  42. Applications of CRISPR-Cas in Ageing Research
    Scott Haston, Sara Pozzi, José Mario González-Meljem · 2020 · Springer eBooks
  43. Therapeutic Targeting of RAS Mutant Cancers
    Edward C. Stites, Kendra V. Paskvan, Shumei Kato · 2022 · Cambridge University Press eBooks
  44. A tyrosine kinase protein interaction map reveals targetable EGFR network oncogenesis in lung cancer
    Swati Kaushik, Franziska Haderk, Xin Zhao, Hsien‐Ming Hu, Khyati Niral Shah, Gwendolyn Μ. Jang, Victor R. Olivas, Shigeki Nanjo, John Jascur, Vincent B. Masto et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  45. Targeting Hyperactive Ras Signaling in Pediatric Cancer
    Anya L. Levinson, Kevin Shannon, Benjamin J. Huang · 2024 · Cold Spring Harbor Perspectives in Medicine
  46. Neddylation as a target in PIK3CA-mutated head and neck cancer
    Shorook Na’ara, Zhibin Cui, Adila Izgutdina, Nathan K. VanLandingham, Andrew Nazarenko, Liam C. Woerner, Becky Xu Hua Fu, Luke A. Gilbert, Daniel E. Johnson, Jennifer Rubin Grandis · 2025 · Biochemical and Biophysical Research Communications
  47. Predicting resistance to KRAS inhibitors
    Leslie K. Ferrarelli · 2020 · Science Signaling
  48. Applications of CRISPRi and CRISPRa in Drug Discovery
    Luke A. Gilbert · 2022
  49. Targeting RAS for Cancer Treatment: What a Long, Strange Trip It's Been
    Adrienne D. Cox, Channing J. Der · 2025 · Annual Review of Cancer Biology
  50. KRAS combination strategies: How well aligned is clinical and preclinical research?
    Ernest Nadal, Chiara Ambrogio, David Santamarı́a, Colin R. Lindsay · 2024 · Elsevier eBooks
  51. Genome-wide CRISPR/Cas9 Screens Reveal Shared and Bespoke Mechanisms of Resistance to SHP2 inhibition
    Wei Wei, Mitchell J. Geer, Xinyi Guo, Igor Dolgalev, Neville E. Sanjana, Benjamin G. Neel · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  52. LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS -mutant lung cancers
    Chendi Li, Mohammed Usman Syed, Anahita Nimbalkar, Yi Shen, Cameron Fraser, Zintis Inde, Xingping Qin, Jian Ouyang, Johannes Kreuzer, Sarah Elizabeth Clark et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  53. Simultaneous Targeting of KRAS and CDK4 Synergistically Suppresses Pancreatic Cancer Cells
    Maj-Britt Paulsohn, Klara Henrike Frahnert, Xin Fang, Carolin Schneider, Constanza Tapia Contreras, Günter Schneider, Elisabeth Heßmann, Matthias Dobbelstein · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  54. Concurrent AXL Inhibition Enhances RAS and ERK Inhibitor Efficacy in KRAS -mutant Pancreatic and Lung Cancer
    Yan Ming Ching, Shruthi Narayanan, Jeffrey A. Klomp, Tamara Isermann, Sina Loewe, Wen-Hsuan Chang, Andrew M. Waters, Sheila R. Nicewarner Peña, Elisa Baldelli, Cole P Martin et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  55. Ras and Ras Signaling as a Therapeutic Target in Cancer
    Bailee H. Sliker, Paul M. Campbell · 2021 · Elsevier eBooks
  56. Defining the KRAS-regulated kinome in KRAS-mutant pancreatic cancer
    J. Nathaniel Diehl, Jennifer E. Klomp, Kayla R. Snare, Devon R. Blake, Priya S. Hibshman, Zane D. Kaiser, Thomas S.K. Gilbert, Elisa Baldelli, Mariaelena Pierobon, Bjoern Papke et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  57. Mechanistic Insight on Ras Inhibition Strategies in Cancer Therapy
    Jeiran Pashapour Anoosheh, Abolfazl Barzegar, Mohammad Saeid Hejazi, Nikoo Hasheminejad, Hamid Reza Heidari, Elnaz Mehdizadeh Aghdam · 2021 · Pharmaceutical Sciences
  58. Discovery of a ‘Grail-Shaped’ Drug: Ne-ratinib and the Downregulation of Mutant RAS
    Paul Dent, Andrew Stewart Poklepovic, Laurence A. Booth · 2019 · EMJ Oncology
  59. Targeting Rat Sarcoma Viral Oncogene Homolog for Treatment of Gastrointestinal Cancers
    Hannah Ruth Robinson, Sarah Lindsey Davis, Christopher Hanyoung Lieu · 2023 · Advances in Oncology
  60. Supplementary Figure S10 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
    Marcelo Vailati Negrao, Haniel Alves Araújo, Giuseppe Lamberti, Alissa Jamie Cooper, Neal S. Akhave, Teng Zhou, Lukas Delasos, James Kevin Hicks, Mihaela D. Aldea, Gabriele Minuti et al. · 2023
  61. Supplementary Figure S10 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
    Marcelo Vailati Negrao, Haniel Alves Araújo, Giuseppe Lamberti, Alissa Jamie Cooper, Neal S. Akhave, Teng Zhou, Lukas Delasos, James Kevin Hicks, Mihaela D. Aldea, Gabriele Minuti et al. · 2023
  62. Supplementary Figure S10 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
    Marcelo Vailati Negrao, Haniel Alves Araújo, Giuseppe Lamberti, Alissa Jamie Cooper, Neal S. Akhave, Teng Zhou, Lukas Delasos, James Kevin Hicks, Mihaela D. Aldea, Gabriele Minuti et al. · 2023
  63. Supplementary Figure S10 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
    Marcelo Vailati Negrao, Haniel Alves Araújo, Giuseppe Lamberti, Alissa Jamie Cooper, Neal S. Akhave, Teng Zhou, Lukas Delasos, James Kevin Hicks, Mihaela D. Aldea, Gabriele Minuti et al. · 2023
  64. KatG inactivation generates vulnerabilities in isoniazid resistant strains of Mycobacterium tuberculosis
    Xinyue Wang, William J Jowsey, Chen‐Yi Cheung, Noon E. J. Seeto, Natalie J.E. Waller, Michael T Chrisp, Amanda L. Peterson, Brunda Nijagal, Peter C. Fineran, Gregory Murray Cook et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  65. Upregulation of ELP3 in acinar cells during acute pancreatitis is dispensable for homeostasis, inflammation, regeneration, and cancer initiation
    Elias Aajja, Hélène Lefort, Siam Mahibullah, Marine Leclercq, Katherine J. Aney, Sahar Nissim, Laurent Nguyen, Alain Chariot, Patrick Henriet, Donatienne Tyteca et al. · 2025 · Scientific Reports
  66. Acute Myeloid Leukemia Relapse after Bromodomain Inhibitor Treatment or Chemotherapy is Characterized by Myc-Ras Transcriptional Remodeling
    Benjamin J. Huang, Jeevitha D’Souza, Alexa Rane Batingana, Max Harris, Xinyue Wang, Eugene Hwang, Anica M. Wandler, Michael R. Burgess, Qing Li, Soheil Meshinchi et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  67. Additional file 1 of A global cancer data integrator reveals principles of synthetic lethality, sex disparity and immunotherapy
    Christopher Yogodzinski, Abolfazl Arab, Justin R. Pritchard, Goodarzi, Hani, Luke A. Gilbert · 2021 · Figshare
  68. Additional file 1 of Ferredoxin 1: a gatekeeper in halting lung adenocarcinoma progression through activation of the GPRIN2 signaling pathway
    Liu, Ming, Wu, Shaoxian, Wu, Haoyu, Zhou, You, Zhang, Xinyu, Zhu, Dawei, Jiang, Jingting · 2024 · Figshare
  69. Additional file 2 of Ferredoxin 1: a gatekeeper in halting lung adenocarcinoma progression through activation of the GPRIN2 signaling pathway
    Liu, Ming, Wu, Shaoxian, Wu, Haoyu, Zhou, You, Zhang, Xinyu, Zhu, Dawei, Jiang, Jingting · 2024 · Figshare
  70. MAPK pathway modulation and its implications in KRAS mutant lung adenocarcinoma
    Sergio de Hita Román · 2023 · theses.fr (ABES)
  71. FGFR1 but not S6K1/2 drives intrinsic BRAF inhibitor resistance in melanoma
    Marwan Almoiliqy, Peng Li, Young-Ho Jung, Dorothy Zheng, Abeer Alshambky, Mohamad Karim Koleilat, Michael A. Davies, Lawrence N. Kwong · 2026 · Cell Death Discovery
  72. KRAS G12C inhibitors in KRASG12C-mutated solid tumors: an immunologically informed systematic review and reconstructed individual patient data meta-analysis
    Yici Yan, Leyi Zheng, Hongfei Wang, Leitao Sun, Xing Xu · 2026 · Frontiers in Immunology
  73. KRAS mutations in gastrointestinal cancers: New insights from pathogenic mechanisms to therapeutic challenges
    Xiaojuan Yang, Xue Tao, Weili Qi, Ruihan Luo, Tian Lan, Kunlin Xie, Yunshi Cai, Fengwei Gao, Yinghao Lv, Chang Liu et al. · 2026 · Journal of Pharmaceutical Analysis
  74. KRAS G12C Inhibition Remodels the Non-Small Cell Lung Cancer Surfaceome to Uncover Targetable Vulnerabilities
    Aparna Padhye, Kalisa Kang, Fan Yi Kong, Nicole Sindoni, Qijia Yu, 柏岐 姜, Wen-Hsuan Chang, Oluwadara Coker, Eejung Kim, Julien Dilly et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  75. Reframing cancer therapy through tumor plasticity
    Akansha M. Shah, Bryan Marsh, Frédéric J. de Sauvage · 2026 · Nature Cancer